Table 6 Test-restest reliability of the FH KAP questionnaire
No | KAP Domain | Item Kappa value | Domain Kappa value | Average Kappa value |
|---|---|---|---|---|
Knowledge domain | 0.796 | |||
3 | Description of FH | 0.879 | 0.818 | |
4 | Identification of lipid profile in FH | 0.865 | ||
6 | Prevalence of FH globally | 0.759 | ||
7 | Transmission of FH to first-degree relative | 0.811 | ||
8 | Rate of CAD risk in untreated FH | 0.755 | ||
9 (a) | Age for premature CAD (males) | 0.920 | ||
9 (b) | Age for premature CAD (females) | 0.923 | ||
11 | Genetic test for diagnosis of FH | 0.650 | ||
22 | Target LDL-c in FH | 0.854 | ||
23 | Important family history in FH | 0.695 | ||
24 | Exclusion of the diagnosis of FH | 0.869 | ||
25 | Management options in FH | 0.835 | ||
Awareness domain | ||||
1 | Familiarity with FH | 0.819 | 0.810 | |
2 | Awareness of NICE clinical guideline | 0.769 | ||
15 | Awareness of lipid specialist | 0.920 | ||
19 | Awareness of other FH clinical guidelines | 0.648 | ||
20 | Awareness of FH diagnostic criteria | 0.893 | ||
Practice domain | ||||
5 | Assistance in detection of FH | 0.877 | 0.760 | |
10 | Screening for FH in premature CAD | 0.641 | ||
12 | Family screening in FH patients | 0.507 | ||
13 | Most effective provider in FH detection | 0.622 | ||
14 | Age of FH screening among young person | 0.685 | ||
16 | Referral to lipid specialist | 1.000 | ||
17 | Pharmacotherapy used for hypercholesterolaemia | 0.943 | ||
18 | Combined pharmacotherapy used for severe hypercholesterolaemia | 0.692 | ||
21 | CAD risk stratification in FH | 0.872 | ||